Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy

Nature Clinical Practice Oncology

Volumn 6, Issue 2, 2009, Pages 68-69

  Martinelli, Giovanni ^a   Soverini, Simona ^a   Iacobucci, Ilaria ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MARKETING; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LEUKEMOGENESIS; NOTE; PLEURA EFFUSION; PRIORITY JOURNAL; QUALITY OF LIFE; UNSPECIFIED SIDE EFFECT;

EID: 59549098053     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc1276     Document Type: Note

References (7)

1. Druker B et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417
2. Talpaz M et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 2531-2541
3. Hochhaus A et al. (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109: 2307-2309.
4. Guilhot F et al. (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109: 4143-4150
5. Cortes J et al. (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109: 3207-3213
6. Shah N et al. (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26: 3204-3212
7. Soverini S et al. (2007) Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 92: 401-404